Harvey Norman has long been a staple of Australian retail, operating across furniture, white goods and consumer electronics, and has traditionally been viewed as a slower-growth, blue-chip stock. While the company does maintain an online presence, its large, iconic physical stores remain central to its strategy.Read more

If one thing is clear, it is that the future of global industrial output is increasingly uncertain as economies transition toward electrification, renewable energy and artificial intelligence. Within this shifting landscape, miners such as Iluka Resources (ASX: ILU) — a producer of a range of industrial minerals through its mineral sands operations — occupy a strategically interesting position.Read more

Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more

Bad press is a problem for any company, and bad press involving misleading statements and compliance failures even more so. On 3 October 2025, Fiducian Group Ltd (ASX:FID) announced that ASIC had commenced civil proceedings against one of its subsidiaries, Fiducian Investment Management Services Ltd (FIMS).Read more

A niche business with exposure to multiple market sectors may sound like a contradiction, but the 4WD aftermarket accessories industry is exactly that. While most people think of recreational off-roading, aftermarket accessories are essential across a diverse set of professional users — tradespeople, farmers, miners, land-management agencies, and utility providers all rely on well-equipped 4WD vehicles to operate effectively.Read more

Over the past two to three decades, Chinese manufacturing has supplied the world with cheap and generally reliable tools. For an American business to not only survive this period but prosper is impressive—and worth a closer look.Read more

Finding genuine value in the current market is becoming increasingly difficult. Stock indices are at or near all-time highs.Read more

AFT Pharmaceuticals is a New Zealand-based pharmaceutical business with global ambitions. The company has publicly set a goal of achieving NZ$300 million in revenue by the end of 2027—a target repeated in its 2025 annual report, market release, shareholder letter, and chairman’s address.Read more

Over the past year, Nick Scali’s share price has risen by more than 50%, even as earnings per share fell by around 30%. This decline in earnings growth has been a consistent trend over the past five years.Read more